[Heart and heart-lung transplantation. 3 years' experience in Timone CHU (Marseilles 1985-1988)]

Arch Mal Coeur Vaiss. 1990 Feb;83(2):209-15.
[Article in French]

Abstract

Since December 1985, we have performed 38 transplantations: cardiac (CT) n: 31, cardiopulmonary (CPT) n: 1, or bipulmonary (BPT) n: 6. There were 31 male and 7 female patients, aged 7 to 62, mean 46. In the cardiac group, the cardiomyopathy was primitive in 13, ischemic in 16, valvular in 2. Five patients had undergone one or more previous operations. Three patients had a biventricular assist device (1,6 and 7 days before transplant) for acute cardiac failure. The indication of CPT or BPT was pulmonary artery hypertension (1), silicosis (1), cystic fibrosis (4). There were 4 post-operative deaths in the CT group (12.9%); failure of graft, low cardiac output, pulmonary artery hypertension by multiple pulmonary thrombosis, and 2 deaths in the CPT and BPT groups (28%). The mean post-operative hospital stay was one month. All patients with CT were treated by an initial maintenance bitherapy protocol (cyclosporine, steroids) and observed by myocardial biopsies and echocardiograms. In 40 per cent of the patients, Azathioprine was subsequently added. The patients had 2.1 rejection episode/patient/year, either spontaneously reversed of treated medically. There were two late deaths (2 and 7 months) by refractory rejection. 78 per cent of the patients were alive one year after transplant. All survivors have recovered a normal life, some of them with full-time work.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cardiomyopathies / surgery
  • Female
  • Follow-Up Studies
  • France
  • Graft Rejection
  • Heart Transplantation* / adverse effects
  • Heart Transplantation* / mortality
  • Heart, Artificial
  • Heart-Lung Transplantation* / adverse effects
  • Heart-Lung Transplantation* / mortality
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Postoperative Care
  • Survival Rate

Substances

  • Immunosuppressive Agents